Next Article in Journal / Special Issue
European Union Should Actively Stimulate and Harmonise Neonatal Screening Initiatives
Previous Article in Journal
Pulse Oximetry Values in Newborns with Critical Congenital Heart Disease upon ICU Admission at Altitude
Article Menu

Export Article

Open AccessReview
Int. J. Neonatal Screen. 2018, 4(4), 31;

Newborn Screening for Sickle Cell Disease: Indian Experience

ICMR-National Institute of Immunohaematology, KEM Hospital Campus, Mumbai 400012, India
Author to whom correspondence should be addressed.
Received: 12 September 2018 / Revised: 5 November 2018 / Accepted: 7 November 2018 / Published: 13 November 2018
PDF [399 KB, uploaded 13 November 2018]


Sickle cell disease (SCD) is a major public health problem in India with the highest prevalence amongst the tribal and some non-tribal ethnic groups. The clinical manifestations are extremely variable ranging from a severe to mild or asymptomatic condition. Early diagnosis and providing care is critical in SCD because of the possibility of lethal complications in early infancy in pre-symptomatic children. Since 2010, neonatal screening programs for SCD have been initiated in a few states of India. A total of 18,003 babies have been screened by automated HPLC using either cord blood samples or heel prick dried blood spots and 2944 and 300 babies were diagnosed as sickle cell carriers and SCD respectively. A follow up of the SCD babies showed considerable variation in the clinical presentation in different population groups, the disease being more severe among non-tribal babies. Around 30% of babies developed serious complications within the first 2 to 2.6 years of life. These pilot studies have demonstrated the feasibility of undertaking newborn screening programs for SCD even in rural areas. A longer follow up of these babies is required and it is important to establish a national newborn screening program for SCD in all of the states where the frequency of the sickle cell gene is very high followed by the development of comprehensive care centers along with counselling and treatment facilities. This comprehensive data will ultimately help us to understand the natural history of SCD in India and also help the Government to formulate strategies for the management and prevention of sickle cell disease in India. View Full-Text
Keywords: newborn screening; sickle cell disease; India; tribal; non-tribal; Guthrie spots; cord blood; automated HPLC newborn screening; sickle cell disease; India; tribal; non-tribal; Guthrie spots; cord blood; automated HPLC

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).

Share & Cite This Article

MDPI and ACS Style

Colah, R.B.; Mehta, P.; Mukherjee, M.B. Newborn Screening for Sickle Cell Disease: Indian Experience. Int. J. Neonatal Screen. 2018, 4, 31.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Metrics

Article Access Statistics



[Return to top]
Int. J. Neonatal Screen. EISSN 2409-515X Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top